Track Record

This team has done it before. Twice, at scale.

Drug developers with approvals and exits behind them. Bioinformaticians. AI data scientists. Engineers who ship. Not a software team that hired a chemist, and not a pharma team that hired a data scientist — one group running all three layers at once.

Track Record

Two nanoparticle reformulations. Both exited for billions.

Taking an approved active, re-engineering how it is delivered, and carrying it through approval and exit. That is the exact model behind SAPU003, and this team has already run it end to end.

Abraxane · nab-paclitaxel

$2.9B

Paclitaxel bound to human albumin — no solvent needed. FDA approved January 2005 in metastatic breast cancer, later non-small cell lung and pancreatic. Abraxis BioScience acquired by Celgene for $2.9 billion in 2010.

Cynviloq · polymeric micelle paclitaxel

$1.3B

Paclitaxel inside a diblock copolymer micelle, marketed as Genexol-PM. Sold by Sorrento Therapeutics to NantPharma for up to $1.3 billion.

Same playbook. New target, found by the engine.

Abraxane and Cynviloq went after tumours everyone already knew about — the science was in the delivery. SAPU003 goes after a driver the engine surfaced, in a field nobody was formulating for. The formulation half is the part these people have already proven twice. The target half is what's new.

How It's Built

Three disciplines, one room.

Most companies in this category are one of these wearing another's coat. The gap between a ranked gene list and an IND is where they stall.

Drug development

People who have shipped medicines

Formulation, GMP manufacture, IND-enabling packages, regulatory strategy. Approvals and exits already on the record — not advisors, operators.

Bioinformatics

People who can break the result

Survival analysis, cohort work, biomarker validation. The job is to try to kill a candidate on public patient data before anyone spends money on it.

AI & engineering

People who built the engine

Data scientists and engineers who took 28M abstracts into production on a vector layer, and keep it refreshed. The method is theirs — patent-pending, favorable WIPO ISR.

Proof of Demand

The first two runs were funded work, not science projects.

SAPU003 and SAPU006 were commissioned, scoped and paid for on contract — concept to clinic in 24 months for $1–3M, each. The engine had a budget behind it before it had a company around it.

Who funded it

Sapu Nano is a subsidiary of the Sapu group of companies — the US arm of GMP Biotechnology Limited, a joint venture completed in April 2022 in which Dragon Overseas Capital Limited holds 55% and Oncotelic Therapeutics holds 45%. Dragon Overseas is a British Virgin Islands company affiliated with Golden Mountain Partners, LLC.

sapunano.com →

Then we licensed one back.

PDAOAI holds SAPU003 in pediatric neurology and longevity, in-licensed from Sapu Biosciences. Sapu retains worldwide oncology and the compound IP. That is the model in one sentence: run the engine, prove it on a funded programme, take a field position in what it finds.

See the program →